Total Valuation
PharmGen Science, Inc. has a market cap or net worth of ₩77.79B. The enterprise value is ―.
Market Cap₩77.79B
Enterprise Value―
Share Statistics
PharmGen Science, Inc. has 22,654,366 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding22,654,366
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
PharmGen Science, Inc.’s return on equity (ROE) is -0.80 and return on invested capital (ROIC) is 2.76%.
Return on Equity (ROE)-0.80
Return on Assets (ROA)-0.60
Return on Invested Capital (ROIC)2.76%
Return on Capital Employed (ROCE)0.04
Revenue Per Employee681.39M
Profits Per Employee-459.27M
Employee Count254
Asset Turnover0.89
Inventory Turnover2.25
Valuation Ratios
The current PE Ratio of PharmGen Science, Inc. is ―. PharmGen Science, Inc.’s PEG ratio is 0.00022.
PE Ratio―
PS Ratio0.53
PB Ratio0.62
Price to Fair Value0.62
Price to FCF23.65
Price to Operating Cash Flow6.95
PEG Ratio0.00022
Income Statement
In the last 12 months, PharmGen Science, Inc. had revenue of 173.07B and earned -116.64B in profits. Earnings per share was -5.31K.
Revenue173.07B
Gross Profit109.13B
Operating Income5.99B
Pretax Income-151.10B
Net Income-116.64B
EBITDA10.53B
Earnings Per Share (EPS)-5.31K
Cash Flow
In the last 12 months, operating cash flow was 10.85B and capital expenditures -2.64B, giving a free cash flow of 8.21B billion.
Operating Cash Flow10.85B
Free Cash Flow8.21B
Free Cash Flow per Share362.19
Dividends & Yields
PharmGen Science, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-0.04
52-Week Price Change-29.95%
50-Day Moving Average―
200-Day Moving Average―
Relative Strength Index (RSI)―
Average Volume (3m)46.85K
Important Dates
PharmGen Science, Inc. upcoming earnings date is Aug 18, 2026, TBA (Confirmed).
Last Earnings DateMay 15, 2026
Next Earnings DateAug 18, 2026
Ex-Dividend Date―
Financial Position
PharmGen Science, Inc. as a current ratio of 2.85, with Debt / Equity ratio of 4.09%
Current Ratio2.85
Quick Ratio2.01
Debt to Market Cap0.06
Net Debt to EBITDA-1.51
Interest Coverage Ratio4.30
Taxes
In the past 12 months, PharmGen Science, Inc. has paid -34.46B in taxes.
Income Tax-34.46B
Effective Tax Rate0.23
Enterprise Valuation
PharmGen Science, Inc. EV to EBITDA ratio is 7.15, with an EV/FCF ratio of 19.53.
EV to Sales0.44
EV to EBITDA7.15
EV to Free Cash Flow19.53
EV to Operating Cash Flow14.16
Balance Sheet
PharmGen Science, Inc. has ₩18.94B in cash and marketable securities with ₩6.14B in debt, giving a net cash position of ₩12.80B billion.
Cash & Marketable Securities₩18.94B
Total Debt₩6.14B
Net Cash₩12.80B
Net Cash Per Share₩564.80
Tangible Book Value Per Share₩6.35K
Margins
Gross margin is 64.84%, with operating margin of 3.46%, and net profit margin of -67.39%.
Gross Margin64.84%
Operating Margin3.46%
Pretax Margin-87.31%
Net Profit Margin-67.39%
EBITDA Margin6.09%
EBIT Margin3.46%
Analyst Forecast
The average price target for PharmGen Science, Inc. is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast1.08%
EPS Growth Forecast-84732.75%